Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M203425200 on August 2, 2002

J. Biol. Chem., Vol. 277, Issue 43, 40342-40351, October 25, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/43/40342    most recent
M203425200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murakami, M.
Right arrow Articles by Cavalié, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murakami, M.
Right arrow Articles by Cavalié, A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Pain Perception in Mice Lacking the beta 3 Subunit of Voltage-activated Calcium Channels*

Manabu MurakamiDagger §, Bernd Fleischmann, Carmen De Felipe||, Marc FreichelDagger , Claudia TrostDagger , Andreas Ludwig**, Ulrich WissenbachDagger , Herbert SchweglerDagger Dagger , Franz Hofmann**, Jürgen Hescheler, Veit FlockerziDagger , and Adolfo CavaliéDagger §§

From the Dagger  Pharmakologie und Toxikologie, Universität des Saarlandes, D-66421 Homburg, Germany, § Molecular Pharmacology, Tohoku University School of Medicine, Sendai 980, Japan,  Institut für Neurophysiologie, Universität zu Köln, D-50931 Köln, Germany, || Instituto de Neurosciencias, Universidad Miguel Hernandez, 03550 San Juan de Alicante, Spain, ** Institut für Pharmakologie und Toxikologie, TU München, D-80802 München, Germany, Dagger Dagger  Institut für Anatomie, Universität Magdeburg, D-39120 Magdeburg, Germany

Received for publication, April 9, 2002, and in revised form, July 30, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The importance of voltage-activated calcium channels in pain processing has been suggested by the spinal antinociceptive action of blockers of N- and P/Q-type calcium channels as well as by gene targeting of the alpha 1B subunit (N-type). The accessory beta 3 subunits of calcium channels are preferentially associated with the alpha 1B subunit in neurones. Here we show that deletion of the beta 3 subunit by gene targeting affects strongly the pain processing of mutant mice. We pinpoint this defect in the pain-related behavior and ascending pain pathways of the spinal cord in vivo and at the level of calcium channel currents and proteins in single dorsal root ganglion neurones in vitro. The pain induced by chemical inflammation is preferentially damped by deletion of beta 3 subunits, whereas responses to acute thermal and mechanical harmful stimuli are reduced moderately or not at all, respectively. The defect results in a weak wind-up of spinal cord activity during intense afferent nerve stimulation. The molecular mechanism responsible for the phenotype was traced to low expression of N-type calcium channels (alpha 1B) and functional alterations of calcium channel currents in neurones projecting to the spinal cord.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Voltage-activated calcium channels represent a family of ionic channels that play a crucial role in the nervous system by controlling membrane excitability and neurotransmitter release. Neurones express L-, N-, P/Q-, and R-type calcium channels, which are composed of the pore-forming subunit alpha 1 and the accessory subunits beta , alpha 2delta , (1, 2) and probably gamma  (3). The importance of alpha 1D (L-type), alpha 1B (N-type), alpha 1A (P/Q-type), and alpha 1E (probably R-type) for the function of the nervous system in vivo is underlined by recent studies with genetically engineered mice (4). By contrast, the in vivo function of the four known beta  subunits (beta 1, beta 2, beta 3, beta 4) of calcium channels is less understood. In heterologous expression systems, beta  subunits are required for the functional expression of alpha 1 subunits (5-7), enhance the current density, and shift the voltage dependence of the activation and inactivation of recombinant calcium channels (8-11). Additionally, beta  subunits have been implicated in the modulation of calcium channels by G proteins (12-14). In vivo, the expression of beta  subunits is modified in pathological states such as cardiac dysfunction (15) and diabetes (16). A natural occurring mutation of beta 4 is associated with ataxia and absence seizures in lethargic (lh/lh) mice, and this mutation modifies N- and P/Q-type calcium channels in the brain (17). The targeted disruption of beta 1 is lethal (18). In sympathetic neurones of beta 3-deficient mice, N- and L-type calcium channel currents are reduced, the activation of P/Q type calcium channels is altered, and no difference appears concerning inhibitory effects of norepinephrine on calcium channel currents (19). Such alterations of calcium channel currents in sympathetic neurones might be related to the cardiovascular phenotype of mice lacking the beta 3 subunit (20). Yet, the in vivo functions of the beta 3 subunit of voltage-activated calcium channels are not well established.

As the alpha 1B subunit of N-type calcium channels is primarily associated with the beta 3 subunit in neurones (21, 22), an altered neurotransmitter release at synaptic sites may be expected in the beta 3-deficient mice. Specifically, blockade of N-type calcium channels inhibits tachykinin release from afferent sensory nerves (23). Within the spinal cord, N-type calcium channels show the highest density in the superficial laminae (24, 25). Accordingly, deletion of the alpha 1B subunit (Cav 2.2) (26-28) and intrathecal injection of the N-type channel blocker, omega -conotoxin GVIA (29), reduce the behavior associated with pain in rodents. Furthermore, the beta 3 subunit might also associate with alpha 1A subunits to form P/Q-type calcium channels, which are present in the deeper laminae of the spinal cord (30) and might be involved in nociceptive processing (29). In the present study, we examine the possible function of beta 3 subunits in nociception and sensory processing using a mouse model in which the beta 3 subunit has genetically been deleted. Because dorsal root ganglions (DRG)1 contain the cell bodies of afferent sensory fibers and predominantly express N-type calcium channel currents (31), binding assays, and pharmacological testing on DRG neurones with the selective marker of N-type channels, omega -conotoxin GVIA, were used to determine the expression of alpha 1B in DRG neurones. We have also explored for changes in the voltage dependence and G protein modulation of calcium channel currents in isolated DRG neurones. In vivo, we analyzed the pain-related behavior and the spinal cord response to an intense and persistent barrage of afferent nociceptive impulses (wind-up).

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Generation of beta 3+/- Mice-- The organization of the beta 3 gene (32) and the targeting vector used to generate null mutations of the beta 3 gene are shown in Fig. 1. Linearized targeting constructs were electroporated into R1 embryonic stem (ES) cells, and the cells were selected with G418 and ganciclovir. We identified 3 of 470 ES cell clones with predicted genomic structures for the targeting vector IIMB. Selected ES cell clones were microinjected into C57BL/6 blastocysts and transferred into the uteri of pseudopregnant recipient females. Two independent ES cell clones were transmitted through the germ line. Mice were kept in essentially specific pathogen-free environment.

Construction and Purification of Glutathione-S-transferase (GST)-beta 1b Fusion Protein and Generation of the Antibodies against beta 1b-- Nucleotides 1269-1857 (aa 403-597) of beta 1b (33) were amplified by PCR using the forward primer, 5'-cgg gat ccg agt act tgg aag cct act g, and the reverse primer, 5'-cgg aat tct cag cgg atg tag acg cct t. The amplified cDNA was ligated into the BamHI/EcoRI sites of pGEX-4T2 (Amersham Biosciences). The accuracy was confirmed by sequencing both strands. BL21(DE3) Escherichia coli were transformed with pGEX-4AT2-beta 1b, and protein expression was carried out as previously described (34). A synthetic peptide (584KNELEGWGQGVYIR597) of beta 1b (33) was coupled to keyhole limpet hemocyanin for injection into rabbit 234. Antibody 234 recognizes the GST-beta 1b fusion protein (Mr ~59,000) and native beta 1b in brain and skeletal muscle (Mr ~72,000). It does not recognize a GST-beta 1a fusion protein (Mr ~33,000) or native beta 1a (Mr ~52,000), which is predominantly expressed in skeletal muscle. Other antibodies have been described previously (22). Immunoblots were repeated up to six times. Pooled tissue from up to three animals (brain microsomes) and up to 20 animals (DRGs) per genotype, respectively, were processed. The data shown (Fig. 1, D-E) represent independent, non-stripped, and non-reused blots.

Nociceptive Tests and Rotorod Test-- The test for nociception were performed as described (35). The tail flick response was evoked by a light beam (irradiated heat) or by immersing two thirds of the tail in water at 52 °C. In the hot plate test, mice were placed on a plate (56 °C), and responses were counted when the mouse first licked the hind paws and jumped from the plate (cut-off time, 30 and 60s, respectively). Formalin (25 µl; 2% paraformaldehyde in phosphate-buffered saline) was injected into the plantar surface of the left hind paw. The time spent licking or biting the injected paw was recorded as the nociceptive score. Inflammation was induced by subcutaneous injection of 10 µl of complete Freund's adjuvant (CFA, 0.5 mg/ml Mycobacterium butyricum in paraffin oil and emulsifying agent) into the plantar surface of the left hind paw under short anesthesia with diethyl ether. Before and 60 h after the CFA injection, the animals were placed on a raised grid, and mechanical thresholds were measured using calibrated von Frey hairs. In the rotorod test, mice were trained on the rod for 1 min at rest and 5 min at 16 rpm, and 1 min at rest and 5 min at 24 rpm. For the test, mice were placed on the apparatus facing away from the experimenter and in the direction opposite to the rotating rod while it was moving at 32 rpm (cut off time 5 min). The tests were performed with adult male mice. The genotype of the animals was unknown to the investigator during the tests.

Extracellular Recordings in the Spinal Cord-- Adult male mice (30-40 g) of both genotypes were used for extracellular unit recordings. The anesthesia was induced with diethyl ether and subsequently with pentobarbital (intraperitoneal 0.5 mg/10 g of body weight). To control the deep of anesthesia, the tail vein was canulated, and pentobarbital was given in the form of intravenous bolus (0.05 mg/10 g of body weight) every 20-25 min during the experiment. A laminectomy was performed to expose the spinal segments Th8-Th10, and the thoraxic vertebras were fixed with spinal hooks in a stereotaxic frame. The left sural nerve was exposed and placed on a bipolar electrode for stimulation (Grass). The experiments were started after a recovery period of 30-45 min. Extracellular recordings were made with tungsten microelectrodes of 5 megohms resistance (WPI, Berlin, Germany) contralateral to the stimulated nerve (i.e. in the right spinal cord). Initially, the microelectrode was placed 350-500 µm lateral to the median dorsal spinal vein in the spinal segment Th8 and carefully inserted just under the surface. To search for responsive units, the electrode was driven from this zero point deep through the spinal cord and trains of 50-V pulses (5 ms long) were regularly delivered to the sural nerve. We used a frequency of 0.2 pulses per second (pps) in this searching phase to prevent wind-up. If the test pulses did not evoke spikes within driving distances of maximally 250 µm, the electrode was removed and the searching phase was reinitiated from a new zero point caudal to a previous one. When the test pulses evoked spikes, we first rule out the contribution of receptive fields by stimulating mechanically (brush, pinch) the skin of the back and hind paws on both ipsilateral and contralateral sides of recording. Because the sural nerve was cut distal to the bipolar electrode, responsive units were used for further analysis when no response to cutaneous stimulation was observed. The thresholds were determined with a series of 12 pulses of amplitudes between 10 V and 100 V (5 ms long, 0.2 pps). The wind-up was finally evoked with 50-V pulses (5 ms long) delivered for 16 s at 1 pps. Data were collected and analyzed using the Chart software for the PowerLab system (ADInstruments).

Isolation of DRG Neurones-- DRGs were obtained from adult wild type and beta 3-/- mice, and neurons were dissociated by incubation in the presence of trypsin type I (0.67 mg/ml medium; Sigma) and collagenase type II (4 mg/ml medium; Biochrom, Berlin, Germany) for 20 min. The cell suspension was centrifuged for 5 min, the supernatant withdrawn, and Dulbecco's modified Eagle's medium supplemented by 10% fetal calf serum was added. Isolated neurones were plated onto poly-L-lysine (Sigma)-coated glass cover slips and kept in an incubator. Electrophysiological experiments were performed within 4-16 h after dissociation.

Whole Cell Patch Clamp-- For electrophysiological recordings glass cover slips were placed into a recording chamber and mounted on an inverted microscope. Cells were perfused with extracellular solution, and electrophysiological recordings were started after 10 min. DRG neurons were identified based on their typical morphology using a 40× phase contrast objective. Ba2+ currents (IBa) from wild type and beta 3-/- DRG neurons were recorded using standard whole cell recording techniques (36). IBa was recorded with an EPC-9 amplifier (HEKA). Upon establishment of the whole cell configuration, series resistance, fast and slow capacitance components were compensated using the internal circuit of the EPC-9 amplifier. The currents were leak-subtracted by applying n/4 correction mode. Data were sampled at 10 kHz and filtered at 3.3 kHz. Data were analyzed off line using the Pulse-Fit (HEKA) software package. For further analysis, current traces were imported into Sigmaplot (Jandel Scientific). For display current traces were transferred to CorelDraw (Corel Graphics). All patch clamp experiments were performed at room temperature. Pipettes of 2-3 megohms resistance were prepared on a DMZ Universal Puller from 1.5 mm borosilicate glass capillaries (Clark Electromedical Instruments). The composition of the recording solutions used was the following (in mM): intracellular solution, CsCl 95, CsSO4 40, tetraethylammonium chloride 20, CaCl2 1, EGTA 10, Mg-ATP 3, Hepes 10 pH 7.3 (CsOH); extracellular solution, tetraethylammonium hydroxide 135, BaCl2 10, MgCl2 1.2, Hepes 10, pH 7.4 (tetraethylammonium hydroxide).

Conotoxin Binding Assays-- Whole dorsal root ganglions were isolated and homogenized in 5 volumes of 5 mM TRIS-HCl, pH 7.4, containing a protease inhibitor mix (0.1 mM phenylmethylsulfonyl fluoride, 1 mM phenanthroline, 1 mM iodoacetamide, 1 mM benzamidine, 1 µM pepstatin A, 1 µg/ml antipain, and 1 µg/ml leupeptin). Equilibrium binding of 125I-labeled omega -conotoxin GVIA (Amersham Biosciences) in the absence and presence of 10 nM unlabeled omega -conotoxin GVIA was performed in duplicate at a total incubation volume of 500 µl containing 10 µg of protein. Binding to isolated DRG neurones was performed as follows: intact neurones were incubated in the presence of 50 pM 125I-labeled omega -conotoxin GVIA for 2 h and then washed three times with Dulbecco's modified Eagle's medium containing 0.1% bovine serum albumin. Nonspecific binding measured in the presence of 200 nM unlabeled omega -conotoxin GVIA was less than 20% of total binding. omega -Conotoxin GVIA binding has been quantified by non-linear regression analysis using the SPSS (Statistical Package for Social Sciences) software.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Targeted Disruption of the beta 3 Gene-- The beta 3 gene (Fig. 1A) was mutated by replacing part of its exon 3 and the complete exon 4 (32) with a neomycin resistance gene (neor). Breeding of heterozygous mice generated beta 3 homozygous (beta 3-/-) mice at the rate expected from the Mendelian frequency (160 +/+, 307 +/- and 144 -/-). The beta 3-/- mice grew normally, lived longer than one year, were fertile, and had no obvious symptoms. Offspring were genotyped for the beta 3 mutation by Southern blot analysis. Wild type and mutant alleles were indicated by the presence of a 12- and 8-kb EcoRI fragment, respectively (Fig. 1B). The deletion of the beta 3 gene was confirmed by Northern blot analysis (Fig. 1C) and immunoblotting of brain extracts (Fig. 1D). Additionally, we found no significant differences between wild type and beta 3-/- mice in the expression levels of beta 1, beta 2, and beta 4 proteins in whole brain (Fig. 1D), suggesting that there was no apparent compensatory increase of the expression of other beta  subunits. Furthermore, it is likely that beta 3 subunits are also expressed in other parts of the nervous system. The DRGs contain cell bodies of primary afferent sensory fibers, including myelinated A fibers and unmyelinated C fibers, which project into the spinal cord. Thus, DRG neurones represent a central component of pain pathways, and additionally, isolated DRG neurones represent a well known cell system in studies of neuronal calcium channels (31). Because the expression pattern of beta  subunits in DRG neurones is not known, we analyzed extracts of isolated DRGs using specific antibodies. Western blot analysis detected the beta 3 protein in DRGs from control animals but not from beta 3-/- mice (Fig. 1E). These results indicate that the gene targeting strategy used in the present study results in suppression of beta 3 protein expression in the DRGs of the adult animals that were selected for further experiments. The protein level of the beta 1, beta 2, and beta 4 subunits was very low but detectable (Fig. 1E). As in brain extracts, no significant change in the expression level of beta 1, beta 2, and beta 4 was apparent in extracts of DRGs isolated from beta 3-/- mice.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 1.   Targeted disruption of the calcium channel beta 3 gene. A, beta 3 locus. Organization of exons (filled boxes) and introns (lines). Targeting vector IIMB (second diagram), a 1-kb HincII (H) fragment containing part of exon 3, exon 4, and part of the following intron, was replaced by the neomycin resistance cassette (neor). The bottom diagram shows the structure of the homologous recombination product. E, EcoRI; P, probe; tk, herpes simplex virus thymidin kinase gene. B, identification of beta 3+/+, beta 3+/-, and beta 3-/- mice by Southern (DNA) blot analysis. C, Northern blot of total RNA extracted from whole brain of beta 3+/+, beta 3+/-, and beta 3-/- mice. The blot was hybridized with mouse beta 3 cDNA sequences (nucleotides 291-602); lower panel shows hybridization of the same filter with human beta -actin cDNA. D and E, immunoblot analysis of beta 3 (top), beta 1, beta 2, and beta 4 (bottom) expression in brain (D) an in DRGs (E).

Nociception Is Altered in beta 3-/- Mice-- Because ablation of beta 3 suppresses the expression of beta 3 subunits in the brain and sensory neurones (Fig. 1), it is likely that the deletion of the beta 3 subunit might have an impact on neuronal functioning in various regions of the nervous system and, thus, at different levels of pain processing pathways. It is known that blockers of N-type calcium channels exert spinal antinociceptive actions (37-39). Additionally, P/Q-type calcium channels may be also involved in nociceptive processes at the spinal level (38, 40). Because beta 3 subunits associate to form N- and P/Q-type calcium channels (21, 22, 41), the suppression of beta 3 subunit expression (Fig. 1) likely produces major defects in the nociceptive pathway, and therefore, we analyzed the pain-related phenotype of the beta 3-/- mice in behavioral test for thermal, mechanical, and chemical nociception (42). Responses to acute thermal stimuli were studied using the tail flick (Fig. 2A) and hot plate tests (Fig. 2B). Tail flick is primarily a spinal reflex, whereas a substantial supraspinal component, which involves lifting and licking of the hind paw, is required in the hot plate assay (35). Tail flick latencies were longer in the beta 3-/- mice both when the tail was exposed to heat by irradiation and by immersion in water at 52 °C (Fig. 2A). In the hot plate test, the latencies for licking were also increased and the delay for escape jumping was almost doubled in the beta 3-/- mice (Fig. 2B). Thus, independent of whether spinal or supraspinal components are engaged in the nociceptive response, the thresholds for thermal stimuli appear to be higher in the beta 3-/- mice. By contrast, the responses to acute mechanical stimuli appear to be normal in the beta 3-/- mice since the mechanical thresholds measured with von Frey filaments were similar to the thresholds of wild type mice (Fig. 2C; wild type, 8.12 ± 1.6 mN, n = 10; beta 3-/-, 6.15 ± 0.7 mN, n = 10). To study the role of the beta 3 subunit in persistent pain, we examine the behavior of beta 3-/- mice employing CFA and formalin. CFA was injected in the foot pad of the left hind paw and, within 24-60 h, induced swelling in the injected paw in wild type mice (injected paw, 2.35 ± 0.07 mm, contralateral side, 2.02 ± 0.07 mm, p < 0.05, n = 10) and beta 3-/- mice (injected paw, 2.47 ± 0.09 mm, contralateral side, 2.17 ± 0.06 mm, p < 0.05, n = 10). The degree of swelling of the injected paw was similar in both groups of mice. After 60 h, the mechanical thresholds measured on the ipsilateral injected paw (Fig. 2C; wild type, 1.65 ± 0.4 mN, n = 10; beta 3-/-, 1.40 ± 0.4 mN, n = 10) and on the contralateral paw (wild type, 5.21 ± 0.5 mN, n = 10; beta 3-/-, 3.87 ± 0.6 mN, n = 10) were significantly reduced (p < 0.05) in wild type and beta 3-/- mice when comparing them to the respective thresholds measured before the CFA injection (Fig. 2C; wild type, 8.12 ± 1.6 mN, n = 10; beta 3-/-, 6.15 ± 0.7 mN, n = 10). Thus, CFA induced hyperalgesia on the ipsilateral and contralateral side of injection in both groups of animals. However, no difference between wild type and beta 3-/- mice was detected in the mechanical thresholds measured after CFA induced swelling. It appears, therefore, that beta 3 subunits are not critical for the development of hyperalgesia in the CFA-induced inflammatory pain. The neurochemical signature of the CFA-induced pain is the internalization of substance P receptors in laminae I, II-IV of the spinal cord (43). Considering that N-type calcium channels are primarily restricted to laminae I-II (24, 25) and P type channels are localized in deeper laminae (30), it is likely that alterations of N-type channels in the beta 3-/- mice become more evident in specific assays of nociception, like the formalin-induced inflammation that is associated with internalization of substance P receptors in lamina I (43). Therefore, we examined the responses of the beta 3-/- mice to chemical stimuli in the formalin test, which is also a well established model to study central sensitization events at the spinal level after peripheral inflammatory states (35). Subcutaneous injection of formalin in the hind paw elicits biphasic pain responses in wild type and beta 3-/- mice (Fig. 3A). In phase 1, formalin stimulates the nociceptors generating acute pain, and in phase 2 the inflammation induced by formalin elicits persistent pain. Both, wild type and beta 3-/- mice behaved similarly in phase 1 but the nociceptive behavior during phase 2 was attenuated by 43% in beta 3-/- mice (Fig. 3, A and B). Because the tests for thermal, chemical, and mechanical nociception measure motor responses as end point, we examined possible motor/sedative defects in the beta 3-/- mice. In the rotorod test, the performance of wild type and beta 3-/- mice were indistinguishable (time on the rod: wild type, 64.62 ± 17.0 s, n = 8; beta 3-/-, 41.86 ± 9.8 s, n = 8), indicating that locomotor functions are not altered in the beta 3-/- mice, and thus, the behavioral tests used in the present study delineate the profile of nociception in the beta 3-/- mice. In summary, the beta 3-/- mice showed higher thresholds for acute thermal stimuli, but the responses to mechanical stimuli were not altered either before or after induction of inflammatory pain with CFA. The acute pain induced by formalin was not altered but the persistent pain observed in phase 2 of the formalin test was markedly reduced in the beta 3-/- mice.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 2.   Nociceptive responses of wild type (+/+) and beta 3-deficient mice (-/-) to thermal and mechanical stimuli. A, tail flick latency to noxius heat (heat irradiation, n = 13 for both groups; tail immersion at 52 °C, n = 14 for both groups). B, hot plate test at 56 °C (n = 14 for both groups). C, response to mechanical stimulation with von Frey hairs before and 60 h after injection of CFA (-CFA and +CFA, respectively; n = 10 for both groups). All data are mean ± S.E. and were analyzed by the Mann-Whitney U test (*, p < 0.05)


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 3.   Nociceptive behavior of wild type (+/+) and beta 3-deficient mice (-/-) after subcutaneous injection of formalin into the hind paw. A, time course of licking and biting behavior. B, total duration of nociceptive responses during phase 1 and 2. Data are mean ± S.E. (n = 7 for both groups) and were analyzed by the Mann-Whitney U test (*, p < 0.05)

Neuronal Activity in the Spinal Cord of beta 3-deficient Mice-- Myelinated A fibers and small diameter, unmyelinated C fibers project to the spinal cord and form neuronal pathways that transmit nociceptive information from the peripheral site of injury to the brain. Among the multiple nociceptive pathways, the spinothalamic pathway originates primarily from neurones in the neck of the dorsal horn and terminates in the ventroposterior and ventrobasal thalamus (44). Within the spinal cord, L-type calcium channels are present in the dorsal horn with a density comparable to brain areas. N-type calcium channels show the highest densities in the superficial laminae of the spinal cord (24, 25, 30) and P-type calcium channels in the deeper laminae (30). Because the response to inflammatory pain appears to be preferentially damped by the deletion of beta 3 subunits, we examined in vivo neuronal responses in the spinal cord evoked by stimulation of peripheral nerves. The neuronal activity was recorded deep in the spinal segment Th8, where responsive units of the spinothalamic pathway are expected, and the stimuli were delivered to the sural nerve of the contralateral side (see "Experimental Procedures"). Under these conditions, trains of pulses with amplitudes up to 30 V, which were applied at a frequency of 0.2 pps, evoked a volley of spikes that lasted less than 100 ms (Fig. 4A). With pulse amplitudes of at least 50 V, we detected in wild type and beta 3-/- mice at least two types of responsive units that can be distinguished by the latencies of the evoked spikes (Fig. 4A, lower panels). The latencies shorter than 70 ms probably reflect the contribution of A fibers, whereas longer latencies likely reflect the activation of C fibers. To compare the thresholds for the activation of responsive units in wild type and beta 3-/- mice, we analyzed the spinal activity evoked by pulses with amplitudes between 10 and 100 V. Under the present experimental conditions, stimuli with amplitudes above 50 V evoked maximal spinal activity in wild type and beta 3-/- mice (Fig. 4B). The activity evoked in the spinal cord, however, depends on the frequency of stimulation. During trains of high frequency pulses, the neuronal activity increases spontaneously, a phenomenon that is observed in various nociceptive pathways and is known as wind-up (45). Thus, to examine the wind-up, we selected an amplitude of 50 V to evoke maximal responses (Fig. 4B) and applied trains of pulses with this amplitude at frequencies higher than 0.2 pps. In several experiments with wild type mice, a moderate wind-up with a delay of 10-15 s was observed with a frequency of 0.5 pps (not shown). Therefore, we compared the wind-up in wild type and beta 3-/- mice at a frequency of 1 pps (Fig. 5). In experiments with wild type mice, we consistently observed maximal activity after 5-7 s of repetitive stimulation, which were accounted for by the increase of spikes with latencies longer than 100 ms (Fig. 5A). Similar wind-up of the spinal cord activity was not observed in paired experiments with beta 3-/- mice (Fig. 5, A and B). Thus, this first characterization of the spinal cord activity in vivo suggests that the activation thresholds of responsive units appears not to be affected, but the wind-up is absent in the beta 3-/- mice.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 4.   Neuronal activity in the spinal cord. Voltage pulses with amplitudes between 10 and 100 V were delivered to the sural nerve at a frequency of 0.2 pps, and the evoked activity was recorded in the contralateral spinal segment Th8. A, representative recordings of spikes (upper panels) produced by responsive units in experiments with a wild type (+/+) and a beta 3-/- mouse (-/-). Voltage pulses with the indicated amplitudes were applied at the time points indicated by arrows. The histograms of spike latencies (lower panels) were compiled from the responses to trains of 12 pulses with an amplitude of 50 V. B, thresholds of responsive units. The spikes observed within 300 ms after each voltage pulse were counted and averaged for trains of 12 pulses (frequency, 0.2 pps; duration, 5 ms). To estimate the activity evoked by a given pulse amplitude, the averaged number of spikes of the corresponding train of pulses was normalized to the maximal value obtained with pulse amplitudes between 10 and 100 V. Each symbol represents a different experiment (wild type mice, upper panel, n = 5; beta 3-/- mice, lower panel, n = 4). Stimuli above 50 V produced maximal spinal cord activity in wild type and beta 3-/- mice.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 5.   Spinal cord activity during high frequency stimulation. Pulses of 50 V amplitude that evoked maximal spinal cord activity (Fig. 4B) were applied at a frequency of 1 pps. A, high frequency stimulation of the responsive units characterized in Fig. 4A. During a train of 16 pulses (upper panel), the evoked activity increased rapidly within the first 5 s (wind-up) and remained elevated up to 16 s in the experiment with the wild type mouse (+/+, middle panel). Similar wind-up was not observed in the beta 3-/- mouse (-/-, lower panel). B, wind-up during high frequency (1 pps) trains of pulses (amplitude, 50 V; duration, 5 ms). The increase of evoked activity was estimated as the number of spikes, which were observed within 500 ms after each pulse divided by the number of spikes evoked by the first pulse. Different symbols represent the mice characterized in Fig. 4B (wild type mice, left panel, n = 5; beta 3-/- mice, right panel, n = 4).

Calcium Channel Currents in DRG Neurones-- The previous results pinpoint the nociceptive defects resulting from the deletion of beta 3 subunits to the spinal level (Figs. 2-5). Because the expression of beta 1, beta 2, and beta 4 subunits appears unaltered in DRG neurones of beta 3-deficient mice (Fig. 1), the alpha 1A, alpha 1B, alpha 1C, alpha 1D, and alpha 1E subunits, which have been detected in murine DRG neurones (46), might be associated either with beta 1, beta 2, or beta 4 subunits in the beta 3-deficient mice. To determine the functioning of neuronal calcium channels in the beta 3-deficient mice, we recorded whole cell barium currents (IBa) in isolated DRG neurones. Depolarizing voltage steps were applied from holding potentials of -50 and -110 mV, and difference currents were obtained by subtracting the records at -100 mV from the respective traces at -50 mV (Fig. 6). The large variability of DRG neurones concerning cell size and calcium channel expression (47, 48) precluded, however, a quantitative analysis of current amplitudes. Another observation in this series of experiments was that the activation and inactivation time courses of compound and difference currents were similar in beta 3-/- DRG neurones and controls (Fig. 6A). Because the expression of beta  subunits speeds up the activation and inactivation of recombinant calcium channels (e.g. 10) and antisense depletion of beta  subunits produces the converse effects in DRG neurones (49), this observation indicates that beta 1, beta 2, or beta 4 are able to replace beta 3, at least, in what concerns activation and inactivation. Additionally, the coexpression of beta  with alpha 1 subunits shifts the membrane potential required for channel opening to more hyperpolarized potentials (1, 2). We observed that the peak of the aggregate whole cell current measured at a holding potential of -110 mV was typically at -10 mV in control and at 0 mV in the beta 3-/- mutants (Fig. 6A). As can be seen in the normalized current-voltage relationships obtained at a holding potential of -70 mV (Fig. 6B), the whole cell current activation is shifted by ~8 mV to more depolarized potential in beta 3-/- neurones when compared with wild type. The activation midpoints in the normalized curves of Fig. 6B are -15.4 and -23.5 mV for beta 3-/- and wild type neurones, respectively. When the current voltage relationships of the individual neurones were fitted with a Boltzmann equation as described previously (50), the calculated potentials for half-activation in beta 3-/- and wild type neurones were -9.1 ± 1.1 mV (n = 17) and -18.1 ± 2.1 mV (n = 11), respectively. A similar shift in the voltage dependence of calcium channel currents was observed in sensory neurones treated with generic anti-beta -antisense oligonucleotides (50). Because beta  subunits have been implicated in the G protein-mediated inhibition and voltage-dependent facilitation of neuronal calcium currents (13, 14), an abnormal modulation of whole cell calcium channel current by G proteins is expected in the beta 3-deficient mice. As previously reported (51, 52), we found that activation of G proteins with GTP-gamma -S slowed the activation kinetics of calcium channel currents and reduced the current amplitude in wild type DRG neurones (Fig. 7A). Depolarizing prepulses accelerated the activation of whole cell calcium channel currents, increased the current amplitude and shifted the current-voltage relationship to more negative potentials (Fig. 7A), in line with the voltage-dependent unblocking of G protein-mediated inhibition of neuronal calcium channels (53, 54). The prepulse facilitation resulted in a voltage-dependent facilitation of calcium channel currents (Fig. 8A). By contrast, we found that depolarizing prepulses sped up the activation time course of whole cell calcium channel currents after dialysis of GTP-gamma -S in the majority of beta 3-/- DRG neurones (9 of 13), but no increase of current amplitude was observed, and accordingly, there was no shift in the current-voltage relationship (Fig. 7B). Thus, the main difference between this group of beta 3-/- neurones and wild type neurones is observed in the degree of prepulse facilitation of whole cell calcium currents (Fig. 8, A and B). This observation is in line with previous studies, which showed that the degree of facilitation of recombinant calcium channels is strongly dependent on the expressed beta  subunit, although the activation time course of whole cell currents facilitated by a prepulse is similar for all beta  subunits (55). In the remaining beta 3-/- DRG neurones (4 of 13), GTP-gamma -S had no effect at all and depolarizing prepulses produced an strong inactivation of calcium channel currents (Fig. 8B). All in all, this first electrophysiological characterization of DRG neurones of beta 3-deficient mice indicates that the voltage-dependent facilitation of calcium channel currents is altered and the voltage dependence of the activation is shifted to more depolarized potentials, although the time course of activation and inactivation is apparently normal.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 6.   Voltage dependence of calcium channel currents in DRG neurones. Whole cell currents (IBa) were evoked from various holding potentials (HP) with depolarizing pulses to potentials between -40 and +40 mV in 10-mV increments. A, representative whole cell current families from DRG neurones of wild type (left panels, +/+) and beta 3-/- mice (right panels, -/-) elicited from the indicated holding potentials. Difference currents were obtained by subtracting current traces at HP = -50 mV from the respective traces at HP = -110 mV. In the wild type neurone, the I-V relationships obtained with holding potentials of -110 mV (continuous line) and -50 mV (dotted line) show peaks of IBa amplitude at -10 mV and 0 mV, respectively. IBa evoked in the beta 3-/- neurone from both holding potentials peaked at 0 mV. B, activation of whole cell currents in response to depolarizing pulses from a holding potential of -70 mV. Current amplitudes were normalized (filled circles, continuous line: wild type, n = 11; open circles, dotted line: beta 3-/- neurones, n = 17). The activation midpoints were -23.5 mV and -15.4 mV for wild type and beta 3-/- neurones, respectively.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 7.   Voltage-dependent facilitation of calcium channel currents in DRG neurones. After cell dialysis with GTP-gamma -S (500 µM), whole cell currents were elicited with test pulses from a holding potential of -70 mV to potentials between -30 mV and +30 mV. The voltage-dependent facilitation was induced with a prespulse to +80 mV. Superimposed are consecutive whole cell current traces obtained without (1) and with (2) prepulses at the test potentials indicated on the left (upper panels). The I-V relationships (bottom panels) show whole cell current amplitudes measured 10 ms after onset of test pulses without (1, dotted line) and with prepulse (2, continuous line). The representative example from a wild tpye DRG neurone (A) shows the slow activation of calcium channel currents after dialysis with GTP-gamma -S (1) and the prepulse-dependent facilitation (2). Prepulses induced also a shift of the I-V relationship to hyperpolarizing potentials. As illustrated in the recordings from a beta 3-/- neurone (B), prepulses sped up the activation of whole cell currents in beta 3-/- DRG neurones but had almost no effect on the I-V relationship.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 8.   Prepulse facilitation. Summary of experiments with DRG neurones in the absence (control) and presence of GTP-gamma -S (500 µM) is shown. Calcium channel current amplitudes were measured 10 ms (full circles) and 49 ms (open squares) after the onset of the test pulse. Facilitation was calculated as the ratio of current amplitudes obtained with and without the prepulse to +80 mV. A, prepulse facilitation is seen in wild type neurones at all potentials (n = 12). B, the majority of beta 3-/- neurones exhibited almost no prepulse facilitation (middle panel, n = 9). In an small number of beta 3-/- neurones (right panel, n = 4), prepulses induced strong inactivation of whole cell currents (inset; 1, no prepulse; 2, with prepulse; calibration bars, 20 ms and 500 pA). The values are mean ± S.E.

Expression of Calcium Channel alpha 1B Subunits in Dorsal Root Ganglions-- In murine DRG neurones, alpha 1B, alpha 1A, as well as alpha 1C, alpha 1D, and alpha 1E have been detected with specific antibodies (46). Considering this wide expression of alpha 1 subunits in DRG neurones, the deletion of the beta 3 subunit (Fig. 1) could alter in principle N-, P/Q-, L- and R-type calcium channels. In sympathetic neurones of beta 3-deficient mice, N-type calcium channel current densities are reduced, while P/Q-type current densities appear to be normal (19). At the synaptic sites in the spinal cord, N-type calcium channels appear to mediate neurotransmitter release (56, 57). As a consequence, beta 3 deletion could be important for nociception and sensory processing due to the reduction of N-type calcium channels in DRG neurones, as indicated by our whole cell current recordings (Fig. 6). Because the N-type component of calcium currents appears to be variable within the heterogeneous population of DRG neurones (47, 48), we first analyzed the expression of alpha 1B in DRG homogenates using binding assays with 125I-labeled omega -conotoxin GVIA, a N-type channel blocker. The specific binding estimated with increasing concentrations of 125I-labeled omega -conotoxin GVIA was reduced by a factor of ~2 in homogenates of beta 3-/- DRG neurones (Fig. 9A). This result suggests that the expression of alpha 1B is reduced in the mutant. Because beta  subunits control the membrane targeting of alpha 1 subunits, we repeated binding assays with intact neurones to estimate the expression of alpha 1B in the membrane. As in the experiments with DRG homogenates (Fig. 9A), the specific binding at a saturating concentration of the N-type blocker was reduced in intact DRG neurones (Fig. 9B), indicating that the number of N-type calcium channels present in the membrane of DRG neurones is reduced in the beta 3-deficient mice. Because these observations suggest that the proportion of N-type currents is reduced in the mutant mice, we determine the inhibitory effects of omega -conotoxin GVIA on whole cell currents of DRG neurones. As reported previously for sympathetic neurones (19), we observed that the percentage of current inhibition by omega -conotoxin GVIA ranges from 37% to 70% in wild type and from 0% to 68% in beta 3-/- DRG neurones. The cumulative distributions indicate, however, that the percentage of inhibition is often less than 25% in beta 3-/- DRG neurones (Fig. 9C, lower panel). On average, the inhibitory effects of omega -conotoxin GVIA are less pronounced in beta 3-/- than in wild type DRG neurones (Fig. 9C, upper panel). Thus our binding studies and pharmacological experiments with omega -conotoxin GVIA imply that the number of functional N-type calcium channels and, consequently, the proportion of N-type calcium channel currents are reduced in DRG neurones of beta 3-deficient mice.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 9.   Binding of omega -conotoxin GVIA (omega CTX) to DRG neurones. A, specific omega CTX binding in homogenates of dorsal root ganglions from wild type (+/+, full circles) and beta 3-/- mice (-/-, open circles). Apparent Bmax values are significantly different (+/+: 25.08 fmol/mg protein (95% confidence interval 0.76-1.27); -/-: 13.21 fmol/mg protein (95% confidence interval 0.43-0.65)), whereas KD values do not differ significantly (KD range 1.1 to 8.9 pM). Experiments have been performed in duplicate with DRGs isolated from 60 mice. B, specific omega CTX binding to intact DRG neurones (~14,400 neurones per determination) isolated from wild type (filled box, n = 7) and beta 3-/- mice (open box, n = 6). C, inhibition of whole cell calcium channel currents by omega CTX (3 µM) in DRG neurones. Whole cell currents were elicited by depolarizations (100 ms long) to -10 mV from a holding potential of -70 mV. The percentage of inhibition was calculated from peak current amplitudes obtained before and after (50-100 s) bath application of omega CTX. Whole cell currents of beta 3-/- neurones (upper panel, open box, n = 10) are less susceptible to inhibition by omega CTX than wild type neurones (upper panel, filled box, n = 6). As seen in the cumulative probability plots for wild type (lower panel, continuous line, n = 6) and beta 3-/- neurones (lower panel, dotted line, n = 10), omega CTX rarely inhibits whole cell currents of beta 3-/- neurones by more than 25%. The values represent mean ± S.E., the asterisks indicate p < 0.05, Student's t test.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In the present study, we examined the role of the beta 3 subunit of calcium channels in the pain perception. The use of a gene-targeting strategy to suppress the expression of beta 3 subunits allowed the analysis throughout various levels, including protein expression and calcium channel currents in single DRG neurones, functioning of neuronal circuits in the spinal cord of anesthetized animals, and nociceptive behavior in awake mice. Our results show that beta 3 subunits are critically involved in the function of nociceptive pathways and, thus, delineate the in vivo function of one of the so-called auxiliary subunits of voltage-dependent calcium channels.

In behavioral assays, we studied the thermal, mechanical, and chemical nociception of the beta 3-/- mice. Responses to acute mechanical and thermal stimuli were not altered or only moderately increased in the beta 3-/- mice, respectively (Fig. 2). Similarly, the thresholds for activation of responsive units in the spinothalamic pathway were not apparently changed in the beta 3-/- mice (Fig. 4). However, the formalin test, which is based on the measurement of licking/biting time as a robust predictor for nociception (42), revealed that beta 3-/- mice develop weak hyperalgesia/allodynia after inflammation because the nociceptive behavior was strongly damped in the tonic, inflammatory phase 2 (Fig. 3). In this respect, the response of beta 3-/- mice compares to the behavior of mice lacking the alpha 1B subunit, which also develop weak hyperalgesia/allodynia after formalin inflammation (26-28). This parallel is in accordance with our finding that DRG neurones of beta 3-/- mice have fewer binding sites for omega -conotoxin GVIA, a blocker of N-type calcium channels (Fig. 9). Our binding and pharmacological studies with omega -conotoxin GVIA (Fig. 9), furthermore, also suggest that the deletion of the beta 3 subunit reduced the membrane expression of alpha 1B. The contribution of L-type calcium channel currents to the development of formalin-induced hyperalgesia seems unlikely, although our results do not rule out a reduction of L-type current in DRG neurones of beta 3-/- mice. When L-type blockers are administered systemically, antinociceptive effects have been observed in rats using the formalin test (e.g. Ref. 58). However, direct application of L-type blockers to the surface of the spinal cord, which is equivalent to intrathecal injection, has no effect on the excitability of dorsal horn neurones produced by formalin inflammation in the rat (38). Accordingly, intrathecal injection of specific blockers of L-type calcium channels has no effect on the nociceptive behavior of rodents either during the early phase or during the late phase of the formalin test (29, 39). Unfortunately, a comparison between the phenotypes of beta 3-, alpha 1C-, and alpha 1A-deficient mice is not possible because alpha 1C (Cav 1.2) and alpha 1A (Cav 2.1) deletion were embryonic lethal and generate strong neurological deficits, respectively (59, 60). Nevertheless, application of the P-type blocker omega -agatoxin IVA to the surface of the spinal cord selectively blocks the excitability of dorsal horn neurones in phase 2 (38), and accordingly, intrathecal injection of the P-type blocker reduces the nociceptive behavior during the late phase but not during the acute phase of the formalin test in the rat (40). On the other hand, intrathecal injection of the N-type blocker omega -conotoxin GVIA reduces the nociceptive behavior in phase 1 and 2 of the formalin test in mice (39) and rats (29). In the formalin tests that were repeated independently in three laboratories of the authors, no clear differences were observed in the behavior of wild type and beta 3-/- mice during the early phase (Fig. 9). Mice deficient in alpha 1B subunits also behave normally in the phase 1 (26-28). Although the unaltered phase 1 in alpha 1B- and beta 3-deficient mice may reflect compensatory mechanisms, the possibility remains that defects of P-type calcium channels may account partially for the reduced nociceptive responses of beta 3-/- mice in the formalin test. We compared the pain-related behavior of the beta 3-/- mice in formalin and CFA tests, which are based on inflammatory processes that produce distinct neurochemical signatures in the spinal cord. The CFA-induced inflammation produces internalization of substance P receptors in laminae I, II-IV of the spinal cord, while the formalin-induced inflammation appears to induced substance P receptor internalization in lamina I (43). Considering that N-type calcium channels are primarily restricted to laminae I-II (24, 25) and that P type channels are localized in deeper laminae (30), our results (Figs. 2 and 3) favor the in vivo importance of a possible modification of spinal N-type channels by deletion of beta 3 subunits and underscore the importance of possible alterations of P-type calcium channels. Furthermore, deletion of beta 3 subunits appears to have not much effect on the expression but alters the voltage-dependent activation of P/Q-type calcium channels, at least in sympathetic neurones (19). In the bodies of beta 3-/- DRG neurones, we observed a depolarizing shift in the voltage dependence of the activation of compound calcium channels currents (Fig. 6). Thus, deletion of beta 3 alters the function of calcium channels that are expressed in the membrane, in way that makes them less sensitive to membrane depolarization. Additionally, the voltage-dependent facilitation of compound calcium channel currents (Fig. 7 and 8) and, likely, the G protein modulation of calcium channels are altered in beta 3-/- DRG neurones. These defects in the activation and G protein modulation of the expressed calcium channels as well as the low expression of N-type calcium channels (Fig. 9) likely modify the pain perception at the spinal level. To support this conclusion, we studied responsive units in the spinothalamic pathway. In wild type but not in beta 3-/- mice, high frequency stimulation of the sural nerve induced wind-up, which probably represents sensitization at the spinal level (Fig. 5). This defect in the processing of pain perception at the spinal level likely reflects the reduced expression of N-type calcium channels together with altered calcium channel currents induced by the ablation of beta 3. By contrast, spinal and supraspinal nociceptive components account for the low sensitivity in the formalin test of mice lacking the alpha 1E subunit (Cav 2.3) (61).

The importance of calcium channel auxiliary subunits in vivo is underlined by the role of alpha 2delta and beta  subunits in neuroplasticity after nerve injury (62) and in pathological states such as cardiac dysfunction (15) and diabetes (16), respectively. The results of the present study suggest an important in vivo function of beta 3 subunits in the nervous system, specifically, in the pain processing at the level of the spinal cord. It is not known whether the expression of beta 3 subunits is affected in pathological states, but the specific nociceptive action of the deletion of beta 3 subunits indicates that, like alpha 1B (63) and alpha 2delta (64), the beta 3 subunits are important pharmacological targets for the modulation of pain in pathological states.

    ACKNOWLEDGEMENTS

We thank Birgit Spohrer for excellent technical assistance in the in vivo recordings of neuronal activity, Frank Zimmermann, Angus King, and Peter Wollenberg for helpful advice and discussions.

    FOOTNOTES

* This study was supported by grants from the Deutsche Forschungsgemeinschaft and Fonds der Chemie (to V. F.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§§ To whom correspondence should be addressed. Tel.: 49-6841-1626151; Fax: 49-6841-1626402; E-mail: adolfo.cavalie@uniklinik-saarland.de.

Published, JBC Papers in Press, August 2, 2002, DOI 10.1074/jbc.M203425200

    ABBREVIATIONS

The abbreviations used are: DRG, dorsal root ganglions; ES, embryonic stem; GST, glutathione S-transferase; CFA, Freund's adjuvant; pps, pulses per second; N, newton.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Hofmann, F., Biel, M., and Flockerzi, V. (1994) Annu. Rev. Neurosci. 17, 399-418[CrossRef][Medline] [Order article via Infotrieve]
2. Catterall, W. A. (1995) Annu. Rev. Biochem. 64, 493-531[CrossRef][Medline] [Order article via Infotrieve]
3. Kang, M. G., Chen, C. C., Felix, R., Letts, V. A., Frankel, W. N., Mori, Y., and Campbell, K. P. (2001) J. Biol. Chem. 276, 32917-32924[Abstract/Free Full Text]
4. Muth, J. N., Varadi, G., and Schwartz, A. (2001) Trends Pharmacol. Science 22, 526-532[CrossRef][Medline] [Order article via Infotrieve]
5. Gurnett, C. A., and Campbell, K. P. (1996) J. Biol. Chem. 271, 27975-27978[Free Full Text]
6. Brice, N. L., and Dolphin, A. C. (1999) J. Physiol. (Lond) 15, 685-694
7. Bichet, D., Cornet, V., Geib, S, Carlier, E., Volsen, S., Hoshi, T., Mori, Y., and De Waard, M. (2000) Neuron 25, 177-190[CrossRef][Medline] [Order article via Infotrieve]
8. Mori, Y., Friedrich, T., Kim, M. S., Mikami, A., Nakai, J., Ruth, P., Bosse, E., Hofmann, F., Flockerzi, V., Furuichi, T., et al.. (1991) Nature 350, 398-402[CrossRef][Medline] [Order article via Infotrieve]
9. Hullin, R., Singer-Lahat, D., Freichel, M., Biel, M., Dascal, N., Hofmann, F., and Flockerzi, V. (1992) EMBO J. 11, 2033-2038[Medline] [Order article via Infotrieve]
10. Welling, A., Bosse, E., Cavalie, A., Bottlender, R., Ludwig, A., Nastainczyk, W., Flockerzi, V., and Hofmann, F. (1993) J. Physiol. 471, 749-765[Abstract/Free Full Text]
11. De Waard, M., Witcher, D. R., Pragnell, M., Liu, H., and Campbell, K. P. (1995) J. Biol. Chem. 270, 12056-12064[Abstract/Free Full Text]
12. Schneider, T., Igelmund, P., and Hescheler, J. (1997) Trends Pharmacol. Sci. 18, 8-11[CrossRef][Medline] [Order article via Infotrieve]
13. Dolphin, A. C. (1998) J. Physiol. (Lond) 506, 3-11[Free Full Text]
14. Dascal, N. (2001) Trends Endocrinol. Metab. 12, 391-398[CrossRef][Medline] [Order article via Infotrieve]
15. Hullin, R., Asmus, F., Ludwig, A., Hersel, J., and Boekstegers, P. (1999) Circulation 100, 155-163[Abstract/Free Full Text]
16. Iwashima, Y., Abiko, A., Ushikubi, F., Hata, A., Kaku, K., Sano, H., and Eto, M. (2001) Biochem. Biophys. Res. Commun. 280, 923-932[CrossRef][Medline] [Order article via Infotrieve]
17. Burgess, D. L., Biddlecome, G. H., McDonough, S. I., Diaz, M. E., Zilinski, C. A., Bean, B. P., Campbell, K. P., and Noebels, J. L. (1999) Mol. Cell. Neurosci. 13, 293-311[CrossRef][Medline] [Order article via Infotrieve]
18. Gregg, R. G., Messing, A., Strube, C., Beurg, M., Moss, R., Behan, M., Sukhareva, M., Haynes, S., Powell, J. A., Coronado, R., and Powers, P. A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 13961-13966[Abstract/Free Full Text]
19. Namkung, Y., Smith, S. M., Lee, S. B., Skrypnyk, N. V., Kim, H.-L., Chin, H., Scheller, R. H., Tsien, R. W., and Shin, H.-S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 12010-12015[Abstract/Free Full Text]
20. Murakami, M., Yamamura, H., Murakami, A., Okamura, T., Nunoki, K., Mitui-Saito, M., Muraki, K., Hano, T., Imaizumi, Y., Flockerzi, T., and Yanagisawa, T. (2000) J. Cardiovasc. Pharmacol. 36, S69-S73[CrossRef][Medline] [Order article via Infotrieve]
21. Scott, V. E., DeWaard, M., Liu, H., Gurnett, C. A., Venzke, D. P., Lennon, V. A., and Campbell, K. P. (1996) J. Biol. Chem. 271, 3207-3212[Abstract/Free Full Text]
22. Ludwig, A., Flockerzi, V., and Hofmann, F. (1997) J. Neurosci. 17, 1339-1349[Abstract/Free Full Text]
23. Morimoto, H., Matsuda, A., Ohori, M., and Fujii, T. (1996) Jpn. J. Pharmacol. 71, 161-166[Medline] [Order article via Infotrieve]
24. Kerr, L. M., Filloux, F., Olivera, B. M., Jackson, H., and Wamsley, J. K. (1988) Eur. J. Pharmacol. 146, 181-183[CrossRef][Medline] [Order article via Infotrieve]
25. Gohil, K., Bell, J. R., Ramachandran, J., and Miljanich, G. P. (1994) Brain Res. 653, 258-266[CrossRef][Medline] [Order article via Infotrieve]
26. Saegusa, H., Kurihara, T., Zong, S., Kazuno, A., Matsuda, Y., Nonaka, T., Han, W., Toriyama, H., and Tanabe, T. (2001) EMBO J. 15, 2349-2356[CrossRef]
27. Hatakeyama, S., Wakamori, M., Ino, M., Miyamoto, N., Takahashi, E., Yoshinaga, T., Sawada, K., Imoto, K., Tanaka, I., Yoshizawa, T., Nishizawa, Y., Mori, Y., Niidome, T., and Shoji, S. (2001) Neuroreport 12, 2423-2427[CrossRef][Medline] [Order article via Infotrieve]
28. Kim, C., Jun, K., Lee, T, Kim, S. S., McEnery, M. W., Chin, H., Kim, H. L., Park, J. M., Kim, D. K, Jung, S J., Kim, J., and Shin, H. S. (2001) Mol. Cell. Neurosci. 18, 235-245[CrossRef][Medline] [Order article via Infotrieve]
29. Vanegas, H., and Schaible, H. (2000) Pain 85, 9-18[CrossRef][Medline] [Order article via Infotrieve]
30. Westenbroek, R. E., Hoskins, L., and Catterall, W. A. (1998) J. Neurosci. 18, 6319-6330[Abstract/Free Full Text]
31. Carbone, E., and Lux, H. D. (1987) J. Physiol. (Lond) 386, 547-570[Abstract/Free Full Text]
32. Murakami, M., Wissenbach, U., and Flockerzi, V. (1996) Eur. J. Biochem. 236, 138-143[Medline] [Order article via Infotrieve]
33. Pragnell, M., Sakamoto, J., Jay, S. D., and Campbell, K. P. (1991) FEBS Lett. 291, 253-258[CrossRef][Medline] [Order article via Infotrieve]
34. Marquart, A., and Flockerzi, V. (1997) FEBS Lett. 407, 137-140[CrossRef][Medline] [Order article via Infotrieve]
35. De Felipe, C., Herrero, J. F., O`Brien, J. A., Palmer, J. A., Doyle, C. A., Smith, A. J. H., Laird, J. M. A., Belmonte, C., Cervero, F., and Hunt, S. P. (1998) Nature 392, 394-397[CrossRef][Medline] [Order article via Infotrieve]
36. Hamill, O. P., Marty, A., Neher, E., Sakmann, B., and Sigworth, F. J. (1981) Pflügers Arch. 391, 85-100[CrossRef][Medline] [Order article via Infotrieve]
37. Malmberg, A. B., and Yaksh, T. L. (1995) Pain 60, 83-90[CrossRef][Medline] [Order article via Infotrieve]
38. Diaz, A., and Dickenson, A. H. (1997) Pain 69, 93-100[CrossRef][Medline] [Order article via Infotrieve]
39. Murakami, M., Nakagawasai, O., Fujii, S., Kameyama, K., Murakami, S., Hozumi, S., Esashi, A., Taniguchi, R., Yanagisawa, T., Tan-no, K., Tadano, T., Kitamura, K., and Kisara, K. (2001) Eur. J. Pharmacol. 419, 175-181[CrossRef][Medline] [Order article via Infotrieve]
40. Malmberg, A. B., and Yaksh, T. L. (1994) J. Neurosci. 14, 4882-4890[Abstract]
41. Moreno, H., Rudy, B., and Llinas, R. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 14042-14047[Abstract/Free Full Text]
42. Wilson, S. G., and Mogil, J. S. (2001) Behav. Brain. Res. 125, 65-73[CrossRef][Medline] [Order article via Infotrieve]
43. Honoré, P., Menning, P. M., Rogers, S. D., Nichols, M. L., Basbaum, A. I., Besson, J. M., and Mantyh, P. W. (1999) J. Neurosci. 19, 7670-7678[Abstract/Free Full Text]
44. Hunt, S. P., and Mantyh, P. W. (2001) Nat. Rev. Neurosci. 2, 83-91[Medline] [Order article via Infotrieve]
45. Herrero, J. F., Laird, J. M., and Lopez-Garcia, J. A. (2000) Prog. Neurobiol. 61, 169-203[CrossRef][Medline] [Order article via Infotrieve]
46. Murakami, M., Suzuki, T., Nakagawasai, O., Murakami, H., Murakami, S., Esashi, A., Taniguchi, R., Yanagisawa, T., Tan-No, K., Miyoshi, I., Sasano, H., and Tadano, T. (2001) Brain Res. 903, 231-236[CrossRef][Medline] [Order article via Infotrieve]
47. Scroggs, R. S., and Fox, A. P. (1992) J. Physiol. (Lond) 445, 639-658[Abstract/Free Full Text]
48. Diochot, S., Richard, S., and Valmier, J. (1995) Neuroscience 69, 627-641[CrossRef][Medline] [Order article via Infotrieve]
49. Berrow, N. S., Campbell, V., Fitzgerald, E. M., Brickley, K., and Dolphin, A. C. (1995) J. Physiol. (Lond) 482, 481-491[Abstract/Free Full Text]
50. Lambert, R. C., Maulet, Y., Mouton, J., Beattie, R., Volsen, S., De, Waard, M., and Feltz, A. (1997) J. Neurosci. 17, 6621-6628[Abstract/Free Full Text]
51. Dunlap, K., and Fischbach, G. D. (1981) J. Physiol. (Lond) 317, 519-535[Abstract/Free Full Text]
52. Scott, R. H., and Dolphin, A. C. (1986) Neurosci. Lett 69, 59-64[CrossRef][Medline] [Order article via Infotrieve]
53. Ikeda, S. R. (1996) Nature 380, 255-258[CrossRef][Medline] [Order article via Infotrieve]
54. Zamponi, G. W., and Snutch, T. P. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 4035-4039[Abstract/Free Full Text]
55. Feng, Z.-P., Arnot, M. I., Doering, C. J., and Zamponi, G. W. (2001) J. Biol. Chem. 48, 45051-45058
56. Yu, C., Lin, P. X., Fitzgerald, S., and Nelson, P. (1992) J. Neurophysiol. 67, 561-575[Abstract/Free Full Text]
57. Gruner, W., and Silva, L. R. (1994) J. Neurosci. 14, 2800-2808[Abstract]
58. Miranda, H. F., Bustamante, D., Kramer, V., Pelissier, T., Saavedra, H., Paeile, C., Fernandez, E., and Pinardi, G. (1992) Eur. J. Pharmacol. 217, 137-141[CrossRef][Medline] [Order article via Infotrieve]
59. Seisenberger, C., Specht, V., Welling, A., Platzer, J., Pfeifer, A., Kuhbandner, S., Striessnig, J., Klugbauer, N., Feil, R., and Hofmann, F. (2000) J. Biol. Chem. 275, 39193-39199[Abstract/Free Full Text]
60. Jun, K., Piedras-Renteria, E. S., Smith, S. M., Wheeler, D. B., Lee, S. B., Lee, T. G., Chin, H., Adams, M. E., Scheller, R. H., Tsien, R. W., and Shin, H. S. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 15245-15250[Abstract/Free Full Text]
61. Saegusa, H., Kurihara, T., Zong, S, Minowa, O., Kazuno, A., Han, W., Matsuda, Y., Yamanaka, H., Osanai, M., Noda, T., and Tanabe, T. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 6132-6137[Abstract/Free Full Text]
62. Luo, Z. D., Chaplan, S. R., Higuera, E. S., Sorkin, L. S., Stauderman, K. A., Williams, M. E., and Yaksh, T. L. (2001) J. Neurosci. 21, 1868-1875[Abstract/Free Full Text]
63. Cox, B. (2000) Curr. Rev. Pain. 4, 488-498[Medline] [Order article via Infotrieve]
64. Rice, A. S., and Maton, S. (2001) Pain 94, 215-224[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. Murakami, T. Ohba, F. Xu, E. Satoh, I. Miyoshi, T. Suzuki, Y. Takahashi, E. Takahashi, H. Watanabe, K. Ono, et al.
Modified Sympathetic Nerve System Activity with Overexpression of the Voltage-dependent Calcium Channel {beta}3 Subunit
J. Biol. Chem., September 5, 2008; 283(36): 24554 - 24560.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Jeon, I. Song, W. Guido, K. Kim, E. Kim, U. Oh, and H.-S. Shin
Ablation of Ca2+ Channel {beta}3 Subunit Leads to Enhanced N-Methyl-D-aspartate Receptor-dependent Long Term Potentiation and Improved Long Term Memory
J. Biol. Chem., May 2, 2008; 283(18): 12093 - 12101.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. J. Field, P. J. Cox, E. Stott, H. Melrose, J. Offord, T.-Z. Su, S. Bramwell, L. Corradini, S. England, J. Winks, et al.
Identification of the {alpha}2-{delta}-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin
PNAS, November 14, 2006; 103(46): 17537 - 17542.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Badou, M. K. Jha, D. Matza, W. Z. Mehal, M. Freichel, V. Flockerzi, and R. A. Flavell
Critical role for the beta regulatory subunits of Cav channels in T lymphocyte function
PNAS, October 17, 2006; 103(42): 15529 - 15534.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
P. Weissgerber, B. Held, W. Bloch, L. Kaestner, K. R. Chien, B. K. Fleischmann, P. Lipp, V. Flockerzi, and M. Freichel
Reduced Cardiac L-Type Ca2+ Current in Cav{beta}2-/- Embryos Impairs Cardiac Development and Contraction With Secondary Defects in Vascular Maturation
Circ. Res., September 29, 2006; 99(7): 749 - 757.
[Abstract] [Full Text] [PDF]


Home page
JGPHome page
T. Yasuda, R. J. Lewis, and D. J. Adams
Overexpressed Cav{beta}3 Inhibits N-type (Cav2.2) Calcium Channel Currents through a Hyperpolarizing Shift of "Ultra-slow" and "Closed-state" Inactivation
J. Gen. Physiol., March 29, 2004; 123(4): 401 - 416.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Murakami, H. Yamamura, T. Suzuki, M.-G. Kang, S. Ohya, A. Murakami, I. Miyoshi, H. Sasano, K. Muraki, T. Hano, et al.
Modified Cardiovascular L-type Channels in Mice Lacking the Voltage-dependent Ca2+ Channel {beta}3 Subunit
J. Biol. Chem., October 31, 2003; 278(44): 43261 - 43267.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/43/40342    most recent
M203425200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murakami, M.
Right arrow Articles by Cavalié, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murakami, M.
Right arrow Articles by Cavalié, A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement